SynKIR-110

N/A

Report date: 2023/04/06 09:34:20

Base Information

Drug NameSynKIR-110

Drug Alias NameSynKIR-meso CAR-T cellsAnti-mesothelin killer immunoglobulin-like receptor based chimeric antigen receptor T cell therapy (Verismo Therapeutics)KIR-CAR-meso (Verismo Therapeutics)SynKIR-mesoSynKIR™-110

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-Mesothelin

TargetsMesothelin

Therapy Area/IndicationsOvarian NeoplasmsCholangiocarcinomaMesothelioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesVerismo Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesVerismo Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsCholangiocarcinomaMesothelioma

Inactive IndicationsN/A

Other Information

ATC CodeN/A